ĐẶC ĐIỂM XÉT NGHIỆM FIBRINOGEN VÀ CA-125 TRONG CHẨN ĐOÁN UNG THƯ BUỒNG TRỨNG NGUYÊN PHÁT TRƯỚC PHẪU THUẬT

Abstract

Objective: The study aimed to compare the characteristics of fibrinogen and CA-125 test values ​​in preoperative ovarian cancer patients with benign ovarian tumors at the Central Obstetrics Hospital from 2019 to 2023. Study design: Cross-sectional descriptive study. Results: Of the total 461 patients, there were 246 cases of ovarian cancer. Of these, the majority were detected at stage 1 (38.2%), followed by stage 3 (9.3%) and stage 2 (5.9%). The non-cancer group accounted for nearly half of the study sample (46.6%). The mean age of cancer patients was 41.89 ± 18.50, significantly higher than that of the benign group (34.69 ± 15.01). Tumor indices such as CA-125 and HE4 increased significantly in the cancer group, 798.87 ± 3377.26 and 206.52 ± 390.35, respectively, compared with 30.95 ± 57.75 and 37.81 ± 12.64 in the benign group, Fibrinogen increased from 3.18 to 4.14 g/L, ROMA test from 4.96% to 39.09%. In addition, inflammatory indices such as leukocytes (7.77 vs 7.15), neutrophils (5.42 vs 4.60), platelets (312.12 vs 272.88) and monocytes (0.61 vs 0.56) also increased significantly. In contrast, lymphocytes decreased slightly in the cancer group (1.74 vs 1.86, p = 0.0155). The risk of ovarian cancer was 2.3 times higher in the 40–59 age group and 4.5 times higher in the ≥60 age group, compared with women <40 years old. Postmenopausal women had a 2.98 times higher risk of ovarian cancer than premenopausal women. Conclusion: The comparison results between the two groups showed a clear and statistically significant difference in most biological and hematological indices (p < 0.0001). Factors such as age, menopause, CA-125, fibrinogen, and elevated ROMA were all clear risk factors associated with ovarian cancer.